Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
Date:12/18/2007

ASHBURN, Va., Dec. 18 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infected diabetic foot ulcers, has commenced dosing.

CollaRx GENTAMICIN TOPICAL is a biodegradable and fully resorbable Gentamicin-Collagen Sponge formulated and manufactured using Innocoll's proprietary collagen-based drug delivery technology, CollaRx. Upon application to a wound, the product releases gentamicin, a broad-spectrum, aminoglycoside antibiotic (having a concentration-dependent mechanism of action), for local action. This achieves a high concentration of drug at the target tissue, while maintaining low systemic levels well below the toxicity threshold.

CollaRx GENTAMICIN TOPICAL represents the clinical development of Innocoll's Gentamicin-Collagen Sponge as a therapy for the treatment and prevention of infected chronic wounds. The product is already approved and marketed in Europe and other non-US territories as a surgical implant for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues. The development of the topical indication is based upon a series of published clinical case studies and anecdotal reports from clinicians where the marketed implant product was applied topically to chronic wounds of various etiologies. This data supports its effectiveness for such clinical applications, particularly in the treatment of infected diabetic foot ulcers.

Chronic ulcerations are often colonized or contaminated with bacterial pathogens that can prevent ulcers from healing. A high proportion of such wounds will become clinically infected and require treatment with antibiotics. Orally and parenterally administered antibiotics are often associated
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... Feb. 8, 2011 The District of Columbia Patients Cooperative ... to provide high quality and affordable medical "marijuana" to qualifying ... implementation of DC,s new medical marijuana program.  The public meeting ... place on Thursday, February 10th at 7:00 pm in Pierce ...
... TUCSON, Ariz., Feb. 8, 2011 MRI Medical Inc. ... as part of its corporate development plan. ... provide our customers with the same superior design, development, ... years," stated Joseph Lee, Xeridiem Medical Devices, Inc.,s President. "Our ...
Cached Medicine Technology:February 10 Town Hall Meeting to Explain DC's New Medical Marijuana Program 2MRI Medical Inc. Changing Name to Xeridiem Medical Devices, Inc. 2
(Date:7/13/2014)... a well-known casket manufacturer from China, has announced its newest ... executive officer has announced a new promotion for its funeral ... prices, from 15 to 26 percent off. , “As far ... in the current market. We are excited to release the ... high quality products for sale. Many of our clients are ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for ... wells as to maintain soil quality. The application of ... a dominant revenue generator for manufacturers in future. The ... costs has led to the adoption of micro irrigation ... caused massive demand for micro irrigation systems, as they ...
(Date:7/13/2014)... 2014 Fuel additives are chemicals, which ... jet fuel, kerosene, and so on, in order to ... reducing the corrosion effects caused by fuels and improving ... any fuel, provide economies of scale in the long ... overall cost of the fuel products. , The various ...
(Date:7/13/2014)... New York, New York (PRWEB) July 13, 2014 ... much to bring attention to the cancer risks associated ... a chance to tell their story to federal regulators, ... of a U.S. Food & Drug Administration (FDA) ... Liebhard LLP reports. According to the Rochester Democrat ...
(Date:7/13/2014)... 13, 2014 Athletes with a certain ... from concussions, according to research presented today at the ... Annual Meeting. The research marks the first of its ... the known physical events that occur after a head ... long allele in the (GT)n genotype were four times ...
Breaking Medicine News(10 mins):Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... ST. LOUIS: Following Advanced Medical Optics' voluntary recall ... lens solution, doctors of optometry from the ... Section concur with the company's decision to remove ... has not been officially determined, health officials from ...
... Biochemical Zoology, a fascinating new selection of papers ... selection, providing insight into how organisms adapt ... ,Dr. James Hicks, Editor in Chief of PBZ, ... "This exciting approach experimental evolution allows ...
... against the myriad strains of the human immunodeficiency virus ... study conducted at the Uniformed Services University of the ... extremely variable, its prevention requires a vaccine effective enough ... can neutralise multiple viral strains. ,The ...
... new study has found that being exposed to pesticides, as ... of developing Parkinsons. ,The study, which is published ... Medicine, one of the BMJ Specialty Journals, states that the ... ,959 people suffering with Parkinsons, as well as 1,989 controls ...
... new research has found that HIV and malaria combine ... ,University of Toronto researchers have exposed the ... and have also discovered how the HIV virus works ... superior vaccines for pregnant women in malaria-ravished regions. ...
... Early data for an investigational device that specifically targets ... , called Tumor-Treating Fields (TTFields), has found that it ... patients with the most common and aggressive type of ... Novo-TTF, uses electrical fields to disrupt tumor growth by ...
Cached Medicine News:Health News:Optometrists Support AMO's Voluntary Contact Lens Solution Recall 2Health News:Research Throws Light on Adaptation of E.coli to Changing Conditions 2Health News:Risk of Parkinsons Increased by Exposure to Pesticide and Head Trauma 2Health News:Malaria and HIV Jointly Affects Pregnant Women and Their Infants 2Health News:Device That Targets Brain Cancer Shows Promising Results 2
... is designed to augment areas ... midface, including the inferior orbital ... in the hollow under the ... implant aids in restoring the ...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Round serrated handle, dull finish....
Medicine Products: